Instem Acquires NOTOCORD; Extends Reach and Capabilities While Further Consolidating Preclinical IT

NOTOCORD Joining Instem Group to Help Drive Growth & Next Stage of Innovation

CONSHOHOCKEN, PA - (BUSINESS WIRE) – September 5, 2016 - -Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that it has acquired NOTOCORD® as part of its mission to further consolidate and harmonize key application areas that are helping customers streamline their research and development processes.

Based in Paris, France, with a presence in the United States, NOTOCORD provides software solutions for data acquisition and analysis in preclinical studies and is a recognized leader in cardiovascular, respiratory, electrophysiology and nervous system research areas. NOTOCORD solutions are used by pharmaceutical companies, contract research laboratories, hospitals and academic research centers around the world.

Instem views the acquisition of NOTOCORD as another important and tangible step in its mission to help clients bring life enhancing products to market faster.

NOTOCORD is a well-respected name in the life sciences software market and its solutions are used every day by top scientists for new drug development research within discovery, safety pharmacology and toxicology studies. Its most widely known solution, NOTOCORD-hem™, is a leading telemetry-based safety pharmacology data collection & analysis system used in preclinical studies.

“The combined customers of NOTOCORD and Instem will be gaining a real advantage,” comments Philippe Zitoun, founder and Chief Executive Officer at NOTOCORD. “Our mission all along was to create technology that was easier and faster to use so our clients can do what they do best, every day. Since we were founded, we have relied on innovative and creative thinking to understand tomorrow’s needs in the marketplace. Becoming part of Instem will allow us to deliver more value, more quickly to more users everywhere. The entire team here at NOTOCORD is excited to be supported by a full complement of resources across Instem’s international offices. Instem shares in our commitment to excellence and is also well known for highly satisfied clients throughout all of the segments that they serve.”

One of the key strategic benefits of this next acquisition for Instem is its ability to more easily enhance its submit™ solution that is supporting FDA’s SEND mandate (Standard for the Exchange of Nonclinical Data) by integrating another key data collection source. A new version of SEND standard (3.1) has recently been published, allowing SEND to include cardiovascular and respiratory Safety Pharmacology studies; this is in addition to toxicity and carcinogenicity studies supported by the current SEND 3.0 standard.

Instem also sees this as an opportunity to integrate data from NOTOCORD systems into its market-leading Provantis® software suite to provide a more seamless approach within preclinical study management, which will help its clients evaluate data and findings more efficiently.

“Notocord has a stellar reputation and a high quality team,” comments Phil Reason, Instem’s Chief Executive Officer. “Having known Philippe and their solutions for many years, we are confident that we will be successful together and that our clients will be very encouraged. As experts in safety pharmacology, the NOTOCORD team joins us just as this becomes a significant and additional focus area for SEND, one of our largest growth opportunities over the next several years. There are also some disruptive innovations in the safety pharmacology marketplace at the moment, so the timing was just right to bring them into the Instem group. We are in a strong position to increase their global reach and penetration with their existing products, while helping them fully launch new and exciting solutions.”

The NOTOCORD team and its applications will be aligned with Instem’s Preclinical Study Management Solutions group, which provides focused software solutions that empower organizations of all sizes to more efficiently collect, review, analyze and manage preclinical safety evaluation study data.

NOTOCORD will quickly be capitalizing on Instem’s global marketing, sales and support capabilities, while ensuring that its track record for delivering high-quality and highly reliable products continues to meet all of its clients’ requirements.

More about NOTOCORD Solutions

NOTOCORD-hem is an advanced software platform designed to acquire, display and analyze physiological signals. Covering Cardiovascular, Respiratory and Nervous system research areas, NOTOCORD-hem offers:

• Over 160 modules for a customized analysis
• In vivo, In vitro and Ex vivo
• Implants and non-invasive telemetry
• Simultaneous acquisition from different sources and systems
• Flexible user interfaces offering easy configuration and displays
• Ultra-fast access to data regardless of experiment file size
• Compliance with GLP & 21 CFR Part 11

The NOTOCORD-fps™ solution is based on a new Field Potential Analysis (FPS) method for analysis supporting an upcoming change in an industry standard for novel safety screening using stem cell data. The Comprehensive in vitro Proarrhythmia Assay, or CiPA, is being considered by regulators and industry work groups and is expected to act as a prerequisite for all non-cardiac drug marketing approvals. The CiPA initiative is intended to move safety pharmacology from a predominantly traditional pharmacodynamics approach to in silico and in vitro drug toxicity assessment.

NOTOCORD-sense® is the next generation platform encompassing new features of its hem and fps solutions along with new exciting capabilities.

To find out more information about NOTOCORD solutions, please visit www.notocord.com.

Instem has been increasing its presence and expanding its capabilities through the opening of new offices, new solution development activities and through key strategic acquisitions.
Instem believes that enabling its clients to more easily access data and help convert it to actionable knowledge is critical for their success in today’s competitive market. Instem has become uniquely positioned across key application areas of the R&D landscape, acting as a strategic partner for its clients throughout the Pharmaceutical, Government Research, Medical Device, Chemical and Agrochemical industries.
Today’s announcement follows recent news of Instem’s acquisition of the Samarind organization and its entry into the Regulatory Information Management (RIM) market.

About Instem

Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions and consulting services increases client productivity by enhancing product development processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

To learn more about Instem solutions and its mission, please visit www.instem.com

Press Contacts:

Instem
Gary Mitchell (US HQ)
gary.mitchell@instem.com 
Tel: 610-941-0990

Julie Jones (UK HQ) 
julie.jones@instem.com 
Tel: +44 (0) 1785 825600